134 related articles for article (PubMed ID: 15166546)
1. Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?
Ridolfo AL; Corbellino M; Tosca N; Capelletti A; Scalamogna C; Galli M; Parravicini C
AIDS; 2004 May; 18(8):1224-6. PubMed ID: 15166546
[No Abstract] [Full Text] [Related]
2. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
[TBL] [Abstract][Full Text] [Related]
3. Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy.
Niehues T; Horneff G; Megahed M; Schroten H; Wahn V
AIDS; 1999 Jun; 13(9):1148-9. PubMed ID: 10397553
[No Abstract] [Full Text] [Related]
4. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen.
Bani-Sadr F; Fournier S; Molina JM
AIDS; 2003 Jul; 17(10):1580-1. PubMed ID: 12824806
[No Abstract] [Full Text] [Related]
5. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy.
Blum L; Pellet C; Agbalika F; Blanchard G; Morel P; Calvo F; Lebbé C
AIDS; 1997 Nov; 11(13):1653-5. PubMed ID: 9365774
[No Abstract] [Full Text] [Related]
6. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma.
Schwartz JD; Howard W; Scadden DT
AIDS; 1999 Feb; 13(2):283-4. PubMed ID: 10202837
[No Abstract] [Full Text] [Related]
7. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir.
Conant MA; Opp KM; Poretz D; Mills RG
AIDS; 1997 Aug; 11(10):1300-1. PubMed ID: 9256954
[No Abstract] [Full Text] [Related]
8. Chemotherapy in HIV-infected patients with Kaposi's sarcoma.
Pechère M; Krischer J; Rutschmann OT
Dermatology; 1997; 195(4):411-2. PubMed ID: 9529573
[No Abstract] [Full Text] [Related]
9. HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?
Philibert P; Chiche L; Caillères S; Allemand J; Rebaudet S; Delord M; Stavris C; Retornaz F; Khiri H; Halfon P
AIDS; 2017 Sep; 31(15):2167-2169. PubMed ID: 28692546
[TBL] [Abstract][Full Text] [Related]
10. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy.
Burdick AE; Carmichael C; Rady PL; Tyring SK; Badiavas E
J Am Acad Dermatol; 1997 Oct; 37(4):648-9. PubMed ID: 9344209
[No Abstract] [Full Text] [Related]
11. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.
Krown SE; Lee JY; Lin L; Fischl MA; Ambinder R; Von Roenn JH
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):149-53. PubMed ID: 16394845
[TBL] [Abstract][Full Text] [Related]
12. Management of HIV associated Kaposi's sarcoma in Malawi.
Mlombe Y
Malawi Med J; 2008 Dec; 20(4):129-32. PubMed ID: 19537395
[TBL] [Abstract][Full Text] [Related]
13. AIDS related Kaposi's sarcoma presenting with palatal and eyelid nodule.
Joshi U; Ceena DE; Ongole R; Sumanth KN; Boaz K; Jeena Priy K; Srikan N
J Assoc Physicians India; 2012 Jul; 60():50-3. PubMed ID: 23405543
[TBL] [Abstract][Full Text] [Related]
14. HIV protease inhibitors as new treatment options for Kaposi's sarcoma.
Barillari G; Sgadari C; Toschi E; Monini P; Ensoli B
Drug Resist Updat; 2003 Aug; 6(4):173-81. PubMed ID: 12962683
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated Kaposi's sarcoma.
Seybold U; Mayr D; Degenhart C; Bogner JR
Infection; 2008 Feb; 36(1):96-7. PubMed ID: 18231715
[No Abstract] [Full Text] [Related]
16. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
17. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
[TBL] [Abstract][Full Text] [Related]
18. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
[TBL] [Abstract][Full Text] [Related]
19. Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma.
Cattelan AM; Trevenzoli M; Aversa SM
Expert Opin Investig Drugs; 2004 May; 13(5):501-13. PubMed ID: 15155125
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
